tetano
Editor, Senior Moderator
Curr Opin Infect Dis
. 2022 Feb 3.
doi: 10.1097/QCO.0000000000000813. Online ahead of print.
Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?
Matteo Bassetti[SUP] 1 [/SUP], Laura Magnasco, Antonio Vena, Federica Portunato, Daniele Roberto Giacobbe
Affiliations
Abstract
Purpose of review: Some patients with coronavirus disease 2019 (COVID-19) may develop pulmonary bacterial coinfection or superinfection, that could unfavorably impact their prognosis.
Recent findings: The exact burden of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in peculiar populations such as patients with COVID-19 remains somewhat elusive, possibly because of wide heterogeneity in methods and endpoints across studies.
Summary: There was important heterogeneity in the retrieved literature on the epidemiology of MRSA lung infection in patients with COVID-19, both when considering all other bacteria as the denominator (relative prevalence ranging from 2% to 29%) and when considering only S. aureus as the denominator (relative prevalence ranging from 11% to 65%). Overall, MRSA is among the most frequent causative agents of pulmonary infection in patients with COVID-19. Improving our ability to rapidly reach etiological diagnosis of bacterial lung infection in COVID-19 patients remains fundamental if we are to improve the rates of appropriate antibiotic therapy in patients with COVID-19 and concomitant/superimposed MRSA infection, at the same time avoiding antibiotic overuse in line with antimicrobial stewardship principles.
. 2022 Feb 3.
doi: 10.1097/QCO.0000000000000813. Online ahead of print.
Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?
Matteo Bassetti[SUP] 1 [/SUP], Laura Magnasco, Antonio Vena, Federica Portunato, Daniele Roberto Giacobbe
Affiliations
- PMID: 35125396
- DOI: 10.1097/QCO.0000000000000813
Abstract
Purpose of review: Some patients with coronavirus disease 2019 (COVID-19) may develop pulmonary bacterial coinfection or superinfection, that could unfavorably impact their prognosis.
Recent findings: The exact burden of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in peculiar populations such as patients with COVID-19 remains somewhat elusive, possibly because of wide heterogeneity in methods and endpoints across studies.
Summary: There was important heterogeneity in the retrieved literature on the epidemiology of MRSA lung infection in patients with COVID-19, both when considering all other bacteria as the denominator (relative prevalence ranging from 2% to 29%) and when considering only S. aureus as the denominator (relative prevalence ranging from 11% to 65%). Overall, MRSA is among the most frequent causative agents of pulmonary infection in patients with COVID-19. Improving our ability to rapidly reach etiological diagnosis of bacterial lung infection in COVID-19 patients remains fundamental if we are to improve the rates of appropriate antibiotic therapy in patients with COVID-19 and concomitant/superimposed MRSA infection, at the same time avoiding antibiotic overuse in line with antimicrobial stewardship principles.